Spots Global Cancer Trial Database for solid tumor
Every month we try and update this database with for solid tumor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors | NCT04172506 | Solid Tumor Lung Cancer HCC | AK105 | 18 Years - 75 Years | Akeso | |
| Safety, Tolerability and Preliminary Efficacy of Engineered Red Blood Cell in Patients With Advanced Malignancies | NCT05707325 | Cancer Solid Tumor Hematologic Mal... | engineered red ... | 18 Years - 75 Years | Westlake Therapeutics | |
| Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | NCT04198766 | Solid Tumor Non-Small Cell ... Melanoma Head and Neck C... Gastric Cancer Renal Cell Carc... Urothelial Carc... | INBRX-106 - Hex... Pembrolizumab 2... Pembrolizumab 4... | 18 Years - | Inhibrx, Inc. | |
| A Trial of ABI-010 & ABI-007 in Patients With Advanced Non-Hematologic Malignancies | NCT00820768 | Solid Tumor | ABI-010 | 18 Years - | Celgene | |
| A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors | NCT05528055 | Solid Tumor Non Hodgkin Lym... | SCR-6920 capsul... SCR-6920 capsul... SCR-6920 capsul... SCR-6920 capsul... | 18 Years - 75 Years | Jiangsu Simcere Pharmaceutical Co., Ltd. | |
| A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma | NCT02423343 | Solid Tumor Non-Small Cell ... Hepatocellular ... | Galunisertib Nivolumab | 18 Years - | Eli Lilly and Company | |
| A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Solid Tumors | NCT05039931 | Breast Cancer Solid Tumor | GNC-035 | 18 Years - | Sichuan Baili Pharmaceutical Co., Ltd. | |
| Study of TRC102 in Combination With Pemetrexed in Cancer Patients | NCT00692159 | Neoplasm | TRC102 + pemetr... | 18 Years - | Tracon Pharmaceuticals Inc. | |
| A Study of Vintafolide (MK-8109) in Participants With Advanced Solid Tumor (MK-8109-011) | NCT02049281 | Solid Tumor | Vintafolide | 20 Years - | Endocyte | |
| Safety Evaluation of a Combination of Brain Radiation Therapy and Bevacizumab (Avastin®) for Treatment of Brain Metastasis | NCT01332929 | Metastatic Mali... | Bevacizumab | 18 Years - 70 Years | Centre Francois Baclesse | |
| A Phase I Dose Finding Study of APO010 in Patients With Solid Tumors | NCT00437736 | Cancer | APO010 | 18 Years - | Valerio Therapeutics | |
| Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors | NCT05361954 | Cancer Cancer of Pancr... Sarcoma Hepatic Metasta... Solid Tumor | STI-1386 | 18 Years - | Sorrento Therapeutics, Inc. | |
| A Study Of Selective Cyclin Dependent Kinase Inhibitor P1446A-05 In Subjects With Advanced Refractory Malignancies | NCT00840190 | Solid Tumor Hematologic Mal... | P1446A-05 | 18 Years - | Piramal Enterprises Limited | |
| A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours | NCT06237413 | Solid Tumor KRAS Mutation-R... | ZG2001 Tosilate... | 18 Years - | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | |
| M1774 Human Mass Balance Study (DDRIVER Solid Tumors 303) | NCT06308263 | Solid Tumor | M1774 [14C]M177... M1774 | 18 Years - | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | |
| Clinical and Pharmacokinetic Trial of Intra-Abdominal Irinotecan | NCT00183859 | Adenocarcinoma Gastric Cancer | irinotecan | 18 Years - | University of Southern California | |
| Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors | NCT03252938 | Solid Tumors Peritoneal Carc... | IMP321 Avelumab | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| The ACC Preclinical Research Platform for Precision Oncology | NCT06339541 | Solid Tumor Hematologic Neo... | 14 Years - | Fondazione del Piemonte per l'Oncologia | ||
| Intervention of CAR-T Against Cervical Cancer | NCT03356795 | Cervical Cancer | Cervical cancer... | 18 Years - 70 Years | Shenzhen Geno-Immune Medical Institute | |
| Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250) | NCT04768296 | Small-cell Lung... | Berzosertib Berzosertib Topotecan | 18 Years - | EMD Serono | |
| One Time Injection of Bacteria to Treat Solid Tumors That Have Not Responded to Standard Therapy | NCT00358397 | Tumors | Clostridium nov... | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Basket Study of AB-106 for the Treatment of Patients With Solid Tumors With NTRK Fusion Gene | NCT04617054 | Solid Tumor | AB-106 | 18 Years - | AnHeart Therapeutics Inc. | |
| The Psychological Impact of COVID-19 on Patients With Solid Malignancies: A Single-Institution Survey Study | NCT05359718 | Solid Tumor | Questionnaire | 18 Years - | The Christie NHS Foundation Trust | |
| A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL) | NCT02509039 | Lymphoma, Non-H... | CC-122 | 20 Years - | Celgene | |
| Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers | NCT03568058 | Advanced Cancer | personalized va... Pembrolizumab | 18 Years - | University of California, San Diego | |
| BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors | NCT00095459 | Neoplasms | Bevacizumab BAY 43-9006 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Clinical Study of Liposomal Paclitaxel in Chinese Patients | NCT00881101 | Solid Tumor | Liposomal pacli... | 18 Years - 70 Years | Nanjing Sike Pharmaceutical Co., Ltd. | |
| GPC3/Mesothelin-CAR-γδT Cells Against Cancers | NCT06196294 | Pancreas Cancer Lung Cancer Liver Cancer Mesothelioma CAR-T Cell Ther... Solid Tumor, Ad... | Cell therapy fo... | 18 Years - 75 Years | Second Affiliated Hospital of Guangzhou Medical University | |
| A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours | NCT05605522 | Pancreatic Duct... Squamous Cell C... Colorectal Canc... Gastric Cancer Ewing Sarcoma NTSR1 Expressin... Neuroendocrine ... | [225]-FPI-2059 [111In]-FPI-205... | 18 Years - | Fusion Pharmaceuticals Inc. | |
| Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI | NCT05381038 | Solid Tumor Gastrointestina... Breast Cancer | QPOP CURATE.AI Azacitidine + d... Azacitidine + p... Azacitidine + i... | 21 Years - 99 Years | National University Hospital, Singapore | |
| Association of Genetic Polymorphisms With Capecitabine-based Chemotherapy Toxicities in Chinese Solid Tumor Patients | NCT03258099 | Solid Tumor Capecitabine Drug-Related Si... Pharmacogenetic... Pharmacokinetic... | detection of ge... | 18 Years - | Peking University First Hospital | |
| A Clinical Study on LM103 for the Treatment of Advanced Solid Tumors | NCT05941936 | Solid Tumor | LM103 | 18 Years - 75 Years | Suzhou BlueHorse Therapeutics Co., Ltd. | |
| D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer | NCT03861156 | Solid Tumor NSCLC EGFR T790M | D-0316 | 18 Years - | InventisBio Co., Ltd | |
| Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas | NCT00553189 | Solid Tumors Lymphomas | ABT-888 Topotecan | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Study of Angiocal® in Patients With Solid Tumors, Investigating Safety, Tolerability, Blood Concentration of Study Drug | NCT01141257 | Solid Tumor | Angiocal® (PRS-... | 18 Years - | Pieris Pharmaceuticals GmbH | |
| STAT3 Inhibitor for Solid Tumors | NCT00955812 | Advanced Cancer Solid Tumor | OPB-31121 | 18 Years - | M.D. Anderson Cancer Center | |
| Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Solid Tumors | NCT05359354 | Solid Tumor | Personalized ne... | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| Randomized Controlled Trial of Integrated Early Palliative Care | NCT03181854 | Advanced Cancer Solid Tumor | Telephone coach... Consultation wi... | 20 Years - | Seoul National University Hospital | |
| Durvalumab Long-Term Safety and Efficacy Study | NCT04078152 | Solid Tumor | Durvalumab | 18 Years - 130 Years | AstraZeneca | |
| Phase I Trial of TGFB2-Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine for Advanced Cancer | NCT00684294 | Carcinoma, Adva... | TGFβ2 Antisense... | 18 Years - | Mary Crowley Medical Research Center | |
| A Study Comparing Non Myeloablative (Flu-TBI) and Reduced Intensity (FLU-BU-ATG) Conditioning in Allogenic Transplantation | NCT00894049 | Allograft Allogeneic Cell... Hematological M... Solid Tumor | reduced intensi... | 18 Years - 65 Years | Institut Paoli-Calmettes | |
| A Phase I/II Study of OBI-3424 in Subjects With Advanced Solid Tumors | NCT03592264 | Solid Tumor Pancreatic Aden... | OBI-3424 | 18 Years - | OBI Pharma, Inc | |
| Safety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours | NCT00697879 | Solid Tumor | CHR-3996 | 18 Years - | Chroma Therapeutics | |
| Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations | NCT03570619 | Metastatic Cast... Metastatic Canc... Solid Tumor | Nivolumab Ipilimumab | 18 Years - | University of Michigan Rogel Cancer Center | |
| Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor | NCT04346381 | Solid Tumor | Camrelizumab Famitinib | 18 Years - 75 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Interest of Medical Hypnosis in Anxious Patients Treated by Radiotherapy | NCT04513444 | Solid Tumor | Relaxation with... Relaxation with... | 18 Years - | Institut Claudius Regaud | |
| A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum | NCT04022213 | Desmoplastic Sm... Peritoneal Canc... Peritoneal Carc... | 131 I-omburtama... WAP-IMRT | 1 Year - | Memorial Sloan Kettering Cancer Center | |
| Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors | NCT01081808 | Neoplasms Tumors Solid Tumors Metastatic Canc... | EGFRBi-armed au... | 18 Years - | Roger Williams Medical Center | |
| Merestinib In Non-Small Cell Lung Cancer And Solid Tumors | NCT02920996 | Carcinoma, Non-... Solid Tumor | Merestinib | 18 Years - | Dana-Farber Cancer Institute | |
| A Study of Recombinant Oncolytic Virus M1(VRT106) in Patients With Solid Tumors | NCT06368921 | Solid Tumor | VRT106 | 18 Years - 75 Years | Guangzhou Virotech Pharmaceutical Co., Ltd. | |
| A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors | NCT02715531 | Solid Tumor | 5-FU Atezolizumab Bevacizumab Gemcitabine Leucovorin Nab-Paclitaxel Oxaliplatin Capecitabine Cisplatin | 18 Years - | Hoffmann-La Roche | |
| Targeting CD276 (B7-H3) Positive Solid Tumors by 4SCAR-276 | NCT04432649 | Solid Tumor | 4SCAR-276 | 1 Year - 75 Years | Shenzhen Geno-Immune Medical Institute | |
| KSH01-R02-101 Solid Tumors | NCT05580796 | Solid Tumor | KSH01 injection | 18 Years - 70 Years | TCRx Therapeutics Co.Ltd | |
| A Clinical Research About CD70-targeted CAR-NKT Cells Therapy Advanced Malignant Solid Tumors | NCT06394622 | Solid Tumor | Cyclophosphamid... | 18 Years - 75 Years | Fudan University | |
| A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors | NCT04731467 | Solid Tumor Non Small Cell ... Pancreatic Canc... Ovarian Cancer Papillary Thyro... Melanoma Colorectal Aden... | CM-24 and Nivol... CM-24, Nivoluma... CM-24, Nivoluma... Nivolumab, Nab ... Nivolumab and N... | 18 Years - | Purple Biotech Ltd. | |
| A Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors | NCT02414516 | Solid Tumor | OBP-801 | 18 Years - | Oncolys BioPharma Inc | |
| A First-in-human (FIH), Multicenter, Open-Label, Phase I Study of PTX-912 in Patients With Locally Advanced/Metastatic Solid Tumors | NCT06190886 | Advanced Cancer Solid Tumor Metastatic Canc... | PTX-912 | 18 Years - | Proviva Therapeutics, Inc. | |
| Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor Malignancies | NCT00215501 | Solid Tumor | Capecitabine 5-Fluorouracil ... Irinotecan Cisplatin | 18 Years - | Dana-Farber Cancer Institute | |
| Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors | NCT05379946 | Solid Tumor | D-1553 IN10018 | 18 Years - | InventisBio Co., Ltd | |
| A Window of Opportunity Study to Investigate Mechanisms of Actions of Novel Therapeutic Agents in Patients With Resectable Solid Tumor Malignancies | NCT03471286 | Solid Tumor | Epacadostat | 18 Years - 100 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| BA Study of IMP4297 (20mg vs 10mg) in Healthy Male Subjects | NCT04351165 | Solid Tumor | IMP4297 | 18 Years - 55 Years | Impact Therapeutics, Inc. | |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors | NCT02541604 | Solid Tumor | Atezolizumab | - 30 Years | Hoffmann-La Roche | |
| Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of FTL001 | NCT06410092 | Solid Tumor | FTL001 | 18 Years - 75 Years | Sound Biopharmaceuticals Ltd. | |
| QUILT-3.028: Study of haNK™ for Infusion in Subjects With Metastatic or Locally Advanced Solid Tumors | NCT03027128 | Solid Tumor | haNK™ for Infus... | 18 Years - | ImmunityBio, Inc. | |
| A Phase I Study of Subutinib Maleate Capsules on Toleration and Pharmacokinetics | NCT01806376 | Solid Tumor | Subutinib Malea... | 18 Years - 70 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors | NCT04720976 | Solid Tumor NSCLC | JAB-3312 Binimetinib Pembrolizumab Sotorasib Osimertinib | 18 Years - | Jacobio Pharmaceuticals Co., Ltd. | |
| A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients | NCT06010342 | Solid Tumor | TL118 Capsule | 18 Years - | Teligene US | |
| A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors | NCT02605083 | Cancer | eFT508 | 18 Years - | Effector Therapeutics | |
| Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid Tumors | NCT04678921 | Solid Tumor Metastatic Canc... Advanced Cancer | TJ210001 | 18 Years - 99 Years | I-Mab Biopharma US Limited | |
| Evaluationn of Tolerability and Safety of CBT101, an Autologous Natural Killer Cell, in Patients With Solid Cancer | NCT04557306 | Solid Tumor | CBT101 cells, e... CBT101 cells, e... | 19 Years - | CHABiotech CO., Ltd | |
| A Study to Assess the Efficacy and Safety of Eltrombopag as a Rescue of Isolated Chemotherapy-induced Thrombocytopenia | NCT02093325 | Solid Tumor | Eltrombopag Placebo | 18 Years - | Chang Gung Memorial Hospital | |
| Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor Malignancies | NCT00215501 | Solid Tumor | Capecitabine 5-Fluorouracil ... Irinotecan Cisplatin | 18 Years - | Dana-Farber Cancer Institute | |
| ALG.APV-527 First-in-human Study | NCT05934539 | Solid Tumor | ALG.APV-527 | 18 Years - | Aptevo Therapeutics | |
| Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma | NCT00413075 | Solid Tumor Lymphoma | oral belinostat | 18 Years - | Valerio Therapeutics | |
| PD-1 Antibody Expressing CAR T Cells for Mesothelin Positive Advanced Malignancies | NCT03030001 | Solid Tumor, Ad... Advanced Cancer | PD-1 antibody e... | 18 Years - 80 Years | Ningbo Cancer Hospital | |
| Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies | NCT04475523 | Solid Tumor | CI-8993 | 18 Years - | Curis, Inc. | |
| Hyperthermia With Flexible Electrode-typed 2-MHz Device During Radiotherapy for Solid Tumors | NCT05282784 | Solid Tumor | Hyperthermia Radiotherapy | 19 Years - 85 Years | Yonsei Hyperthermia Study Group | |
| A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors | NCT02697591 | Advanced Malign... Metastatic Canc... | INCAGN01876 | 18 Years - | Incyte Corporation | |
| NKG2D/CLDN18.2 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumors | NCT05583201 | Gastric Cancer Pancreatic Canc... Solid Tumor | KD-496 | 18 Years - 75 Years | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | |
| A Study of IBI3004 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors | NCT06198426 | Solid Tumor | IBI3004 | 18 Years - 75 Years | Innovent Biologics (Suzhou) Co. Ltd. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
